Please assess the completion status of the following clinical trial:

Trial Title: Immuno-bridging Study of COVID-19 Protein Subunit Recombinant Vaccine

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Clinically healthy subjects aged 18 years and above.~2. Subjects have been informed properly regarding the study and signed the informed consent form.~3. Subjects will commit to comply with the instructions of the investigator and the schedule of the trial.~Exclusion Criteria:~1. Subjects concomitantly enrolled or scheduled to be enrolled in another trial.~2. History of vaccination with any COVID-19 vaccine.~3. History of COVID-19 within 1 month (for mild-moderate disease) or 3 months (for severe disease) prior to enrollment.~4. Evolving mild, moderate, or severe illness, especially infectious disease, or fever (body temperature ≥37.5℃, measured with infrared thermometer/thermal gun).~5. Women who are pregnant or planning to become pregnant during the study period (judged by self-report of subjects and urine pregnancy test results).~6. History of uncontrolled asthma, allergy to vaccines or vaccine ingredients, and severe adverse reactions to vaccines, such as urticaria, dyspnea, and angioneurotic edema.~7. History of blood disorders contraindicating intramuscular injection.~8. Patients with serious chronic diseases (serious cardiovascular diseases, uncontrolled hypertension and diabetes, liver and kidney diseases, malignant tumors, etc.) which according to the investigator might interfere with the assessment of the trial objectives.~9. History of confirmed or suspected immunosuppressive or immunodeficient state or in the previous 4 weeks received a treatment likely to alter the immune response (intravenous immunoglobulins, blood-derived products, or long-term corticosteroid therapy (\> 2 weeks)).~10. History of uncontrolled epilepsy or other progressive neurological disorders, such as Guillain-Barre Syndrome.~11. Subjects receive any vaccination (other than COVID-19 vaccine) within 1 month before and after IP immunization.~12. Subjects plan to move from the study area before the end of study period.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: t

Study Arms:
- COVID-19 Protein Subunit Recombinant Vaccine (Type: EXPERIMENTAL): 2 doses of COVID-19 Protein Subunit Recombinant Vaccine administered with 28 days interval (0.5 mL per dose)
- Active Comparator (Type: ACTIVE_COMPARATOR): 2 doses of Covovax® - recombinant spike protein Nanoparticle Vaccine, administered with 28 days interval (0.5 mL per dose)

Based on this trial design, predict the completion outcome and termination type (if applicable).